The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers

Inge-Marie Obdeijn*, Ritse M. Mann, Claudette C. E. Loo, Marc Lobbes, Eleonora M. C. Voormolen, Carolien H. M. van Deurzen, Geertruida de Bock, Maartje J. Hooning, Hereditary Breast Ovarian Cancer Research Group Netherlands (HEBON)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)


Purpose BRCA2 mutation carriers are offered annual breast screening with MRI and mammography. The aim of this study was to investigate the supplemental value of mammographic screening over MRI screening alone. Methods In this multicenter study, proven BRCA2 mutation carriers, who developed breast cancer during screening using both digital mammography and state-of-art breast MRI, were identified. Clinical data were reviewed to classify cases in screen-detected and interval cancers. Imaging was reviewed to assess the diagnostic value of mammography and MRI, using the Breast Imaging and Data System (BI-RADS) classification allocated at the time of diagnosis. Results From January 2003 till March 2019, 62 invasive breast cancers and 23 ductal carcinomas in situ were diagnosed in 83 BRCA2 mutation carriers under surveillance. Overall screening sensitivity was 95.2% (81/85). Four interval cancers occurred (4.7% (4/85)). MRI detected 73 of 85 breast cancers (sensitivity 85.8%) and 42 mammography (sensitivity 49.9%) (p <0.001). Eight mammography-only lesions occurred. In 1 of 17 women younger than 40 years, a 6-mm grade 3 DCIS, retrospectively visible on MRI, was detected with mammography only in a 38-year-old woman. The other 7 mammography-only breast cancers were diagnosed in women aged 50 years and older, increasing sensitivity in this subgroup from 79.5% (35/44) to 95.5% (42/44) (p

Original languageEnglish
Pages (from-to)581-588
Number of pages8
JournalBreast Cancer Research and Treatment
Issue number3
Publication statusPublished - Jun 2020


  • BRCA mutation carriers
  • Screening
  • MRI
  • Mammography
  • RISK

Cite this